ArticleEClinicalMedicine2021

Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study.

Rui Wan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.